Protective effect of DNA vaccine during chemotherapy on reactivation and reinfection of Mycobacterium tuberculosis

Gene Therapy

Volumn 12, Issue 7, 2005, Pages 634-638

  Ha, S J ^a   Jeon, B Y ^b   Youn, J I ^a   Cho, S N ^b,c   Sung, Y C ^a  

^a Pohang University of Science and Technology (POSTECH)   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c International Vaccine Institute   (South Korea)

Author keywords

Ag85A; Chemotherapy; Double gene DNA vaccine; Mycobacterium tuberculosis; PstS 3

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; ISONIAZID; PLASMID DNA; PYRAZINAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL GROWTH; CHEMOTHERAPY; CONTROLLED STUDY; CORRELATION FUNCTION; DRUG EFFICACY; IMMUNE RESPONSE; IMMUNOTHERAPY; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; REINFECTION; STATISTICAL SIGNIFICANCE; SUPERINFECTION; TH1 CELL; TUBERCULOSIS; VACCINATION;

ANIMALS; ANTITUBERCULAR AGENTS; COLONY COUNT, MICROBIAL; COMBINED MODALITY THERAPY; DNA, BACTERIAL; INTERFERON TYPE II; MICE; MICE, INBRED C57BL; MYCOBACTERIUM TUBERCULOSIS; RECURRENCE; TUBERCULOSIS; TUBERCULOSIS VACCINES; VACCINES, DNA; VIRUS ACTIVATION;

MYCOBACTERIUM; MYCOBACTERIUM TUBERCULOSIS;

EID: 16344395660     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302465     Document Type: Article

References (31)

1. Flynn JL, Chan J. Immunology of tuberculosis. Annu Rev Immunol 2001; 19: 93-129.
2. Kochi A, Nunn P, Dye C, Tayler E. Global burden of disease. Lancet 1997; 350: 142.
3. Kaufmann SH. Is the development of a new tuberculosis vaccine possible? Nat Med 2000; 6: 955-960.
4. Mitchison DA. The action of antituberculosis drugs in short-course chemotherapy. Tubercle 1985; 66: 219-225.
5. Bishai WR et al. Molecular and geographic patterns of tuberculosis transmission after 15 years of directly observed therapy. JAMA 1998; 280: 1679-1684.
6. Barnes PF, Cave MD. Molecular epidemiology of tuberculosis. N Engl J Med 2003; 349: 1149-1156.
7. van Rie A et al. Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. N Engl J Med 1999; 341: 1174-1179.
8. Bandera A et al. Molecular epidemiology study of exogenous reinfection in an area with a low incidence of tuberculosis. J Clin Microbiol 2001; 39: 2213-2218.
9. Caminero JA et al. Exogenous reinfection with tuberculosis on a European island with a moderate incidence of disease. Am J Respir Crit Care Med 2001; 163: 717-720.
10. Denis O et al. Vaccination with plasmid DNA encoding mycobacterial antigen 85A stimulates a CD4+ and CD8+ T-cell epitopic repertoire broader than that stimulated by Mycobacterium tuberculosis H37Rv infection. Infect Immun 1998; 66: 1527-1533.
11. Huygen K et al. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat Med 1996; 2: 893-898.
12. Tascon RE et al. Vaccination against tuberculosis by DNA injection. Nat Med 1996; 2: 888-892.
13. Tanghe A et al. Immunogenicity and protective efficacy of tuberculosis DNA vaccines encoding putative phosphate transport receptors. J Immunol 1999; 162: 1113-1119.
14. Repique CJ, Li A, Collins FM, Morris SL. DNA immunization in a mouse model of latent tuberculosis: effect of DNA vaccination on reactivation of disease and on reinfection with a secondary challenge. Infect Immun 2002; 70: 3318-3323.
15. Taylor JL et al. Pulmonary necrosis resulting from DNA vaccination against tuberculosis. Infect Immun 2003; 71: 2192-2198.
16. Turner J et al. Effective preexposure tuberculosis vaccines fail to protect when they are given in an immunotherapeutic mode. Infect Immun 2000; 68: 1706-1709.
17. Lowrie DB et al. Therapy of tuberculosis in mice by DNA vaccination. Nature 1999; 400: 269-271.
18. Ha SJ et al. Therapeutic effect of DNA vaccines combined with chemotherapy in a latent infection model after aerosol infection of mice with Mycobacterium tuberculosis. Gene Therapy 2003; 10: 1592-1599.
19. Botha T, Ryffel B. Reactivation of latent tuberculosis by an inhibitor of inducible nitric oxide synthase in an aerosol murine model. Immunology 2002; 107: 350-357.
20. Kamath AT et al. Differential protective efficacy of DNA vaccines expressing secreted proteins of Mycobacterium tuberculosis. Infect Immun 1999; 67: 1702-1707.
21. Doria-Rose NA, Haigwood NL. DNA vaccine strategies: candidates for immune modulation and immunization regimens. Methods 2003; 31: 207-216.
22. Mendez S, Belkaid Y, Seder RA, Sacks D. Optimization of DNA vaccination against cutaneous leishmaniasis. Vaccine 2002; 20 3702-3708.
23. Morris S et al. The immunogenicity of single and combination DNA vaccines against tuberculosis. Vaccine 2000; 18 2155-2163.
24. Kong WP et al. Immunogenicity of multiple gene and clade human immunodeficiency virus type 1 DNA vaccines. J Virol 2003; 77: 12764-12772.
25. Wiker HG, Harboe M. The antigen 85 complex: a major secretion product of Mycobacterium tuberculosis. Microbiol Rev 1992; 56 648-661.
26. D'Souza S et al. CD4+ T cells contain Mycobacterium tuberculosis infection in the absence of CD8+ T cells in mice vaccinated with DNA encoding Ag85A. Eur J Immunol 2000; 30: 2455-2459.
27. D'Souza S et al. Improved tuberculosis DNA vaccines by formulation in cationic lipids. Infect Immun 2002; 70: 3681-3688.
28. Romano M et al. Induction of in vivo functional Db-restricted cytolytic T cell activity against a putative phosphate transport receptor of Mycobacterium tuberculosis. J Immunol 2004; 172: 6913-6921.
29. van Pinxteren LA et al. Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells. Eur J Immunol 2000; 30: 3689-3698.
30. Park SH et al. Efficient induction of T helper 1 CD4+ T-cell responses to hepatitis C virus core and E2 by a DNA prime-adenovirus boost. Vaccine 2003; 21: 4555-4564.
31. Ha SJ et al. IL-23 induces stronger sustained CTL and Th1 immune responses than IL-12 in hepatitis C virus envelope protein 2 DNA immunization. J Immunol 2004; 172: 525-531.